Search Results
Your search for this matches 25286 pages
Showing 4551 - 4600Association of Radiation and Procarbazine Dose With Risk of Colorectal Cancer in Survivors of Hodgkin Lymphoma
In a Dutch study reported in JAMA Oncology, Geurts et al found a dose-response relationship between radiotherapy and risk of colorectal cancer among survivors of Hodgkin lymphoma, with the risk being increased with increasing procarbazine dose. Study Details The nested case-control study included...
Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer and High FRα Expression
As reported in the Journal of Clinical Oncology by Ursula A. Matulonis, MD, and colleagues, results from the phase II SORAYA study showed activity of mirvetuximab soravtansine-gynx, an antibody-drug conjugate targeting folate receptor alpha (FRα), in patients with platinum-resistant ovarian cancer...
WHO Launches New Roadmap on Breast Cancer
The World Health Organization (WHO) has released a new Global Breast Cancer Initiative Framework, providing a roadmap to attain targets to save 2.5 million lives from breast cancer by 2040. The new framework recommends that countries implement three pillars of health promotion—early detection,...
Highlights From the 2023 ASCO Gastrointestinal Cancers Symposium
The 2023 ASCO Gastrointestinal Cancers Symposium took place from January 19 to 21 in San Francisco. On this episode, we’re hearing from the presenting authors of three studies reported at that meeting—the SUNLIGHT, SPOTLIGHT, and NAPOLI-3 trials—which examined novel regimens in colorectal, gastric, ...
FDA Approves Sacituzumab Govitecan-hziy for Pretreated Patients With HR-Positive, HER2-Negative Breast Cancer
On February 3, the U.S. Food and Drug Administration (FDA) approved sacituzumab govitecan-hziy (Trodelvy) for patients with unresectable, locally advanced or metastatic, hormone receptor (HR)-positive, HER2-negative (immunohistochemistry [IHC] 0, IHC 1+, or IHC 2+ with a negative in situ...
Challenges of Accurately Identifying HER2-Low Breast Cancers
The newly identified category of “HER2-low” breast cancer has raised many new issues in this malignancy now that the DESTINY Breast-041 trial determined that fam-trastuzumab deruxtecan-nxki (T-DXd) may effectively treat this tumor. Among the issues are challenges in accurately identifying just...
Massage Therapy May Improve Symptom Burden for Pediatric Patients With Hematologic and/or Oncologic Conditions
A new study from University Hospitals (UH) Connor Whole Health found children, adolescents, and young adults with cancer or sickle cell disease treated at a pediatric academic medical center reported clinically significant reductions in pain, stress, and anxiety in response to massage therapy....
Researchers Develop AI Algorithm to Gain New Insights Into Glioblastoma
Researchers have developed an artificial intelligence (AI) algorithm, known as SPHINKS, capable of performing advanced computational analyses to identify potential therapeutic targets for patients with glioblastoma multiforme. The platform may also have applicability in other cancers, according to...
OCRA Issues Consensus Statement Calling for Consideration of Fallopian Tube Removal to Prevent Ovarian Cancer
The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) has shown that general population screening did not significantly reduce ovarian and tubal cancer deaths, and the researchers concluded that such screening cannot be recommended. The findings from the study prompted the Ovarian Cancer ...
Expert Point of View: Emily K. Curran, MD
Moderator of the session, Emily K. Curran, MD, Assistant Professor of Internal Medicine at the University of Cincinnati Cancer Center, in Ohio, said that the data presented by Dr. Short and colleagues demonstrated very impressive event-free and overall survival rates, especially for a disease that...
Ponatinib and Blinatumomab Combination Safe and Effective in Patients With Newly Diagnosed, Ph-Positive ALL
The combination of ponatinib and blinatumomab has led to rapid and durable remissions in patients with newly diagnosed Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), according to data presented at the 2022 American Society of Hematology (ASH) Annual Meeting and...
Neoadjuvant Plus Adjuvant Chemotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Colon Cancer
As reported in the Journal of Clinical Oncology by Morton et al, the European phase III FOxTROT trial has shown that neoadjuvant plus adjuvant oxaliplatin/fluoropyrimidine resulted in a reduced risk of residual disease or disease recurrence vs adjuvant oxaliplatin/fluoropyrimidine in patients with...
Surgical Quality Metric Scoring and Survival Among U.S. Veterans With Early-Stage NSCLC
In a study reported in JAMA Surgery, Heiden et al developed a surgical quality metric scoring system—the Veterans Affairs Lung Cancer Operative quality (VALCAN-O) score—that was associated with overall survival in U.S. veterans undergoing curative-intent surgery for early-stage non–small cell lung...
Consuming Ultraprocessed Foods May Be Linked to Increased Cancer Risk and Mortality
Higher consumption of ultraprocessed foods may be linked to increased cancer burden and mortality, according to a new, UK-based study published by Chang et al in eClinicalMedicine. Ultraprocessed foods are food items which have been heavily processed during their production—such as fizzy drinks,...
Adjuvant Osimertinib Significantly Improves Disease-Free Survival for Patients With Resected EGFR-Mutant NSCLC
The EGFR tyrosine kinase inhibitor osimertinib may improve rates of disease-free survival and reduce the risk of recurrence in patients with resected, EGFR-mutant non–small cell lung cancer (NSCLC), according to a new exploratory analysis of the ADAURA trial published by Roy S. Herbst, MD, PhD,...
Levels of Inflammatory Biomarkers and Survival in Patients Receiving Adjuvant Therapy for Stage III Colon Cancer
In a study reported in JAMA Oncology, Cheng et al found that higher levels of inflammatory biomarkers measured after surgery—but before receipt of chemotherapy—were associated with poorer outcomes in patients with stage III colon cancer enrolled in the CALGB/SWOG 80702 trial of adjuvant...
Study Finds Breast MRI Superior vs Other Supplementary Screening Tests for Detecting Breast Cancer in Patients With Dense Breasts
Compared to other common supplemental screening methods, breast magnetic resonance imaging (MRI) was superior at detecting breast cancer in patients with dense breasts, according to a new study published by Hussein et al in Radiology. Background Breast cancer is one of the leading causes of cancer...
Gap Discovered in Breast Cancer Radiotherapy Recommendations for Patients Aged 70 vs 69 Years
Age-based heuristics may lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new study published by Talcott et al in the International Journal of Radiation Oncology • Biology • and Physics. Background Radiation therapy often is given...
Association of Polygenic Risk Score With Tumor Characteristics and Survival in Patients With Invasive Breast Cancer
In a study reported in the Journal of Clinical Oncology, Josephine M.N. Lopes Cardozo, MD, PhD, and colleagues found that a higher score on a polygenic risk score consisting of 313 common genetic variants (the PRS313) was generally associated with more favorable tumor characteristics in patients...
Uptake of Immune Checkpoint Inhibitors and Survival Among Younger and Older Patients With Advanced NSCLC
In a U.S. cohort study reported in JAMA Oncology, Voruganti et al found that the uptake of immune checkpoint inhibitor therapy for patients with advanced non–small cell lung cancer (NSCLC) has been associated with “modest” improvements in overall survival, particularly among older patients. As...
Momelotinib May Effectively Reduce Anemia and Other Symptoms for Patients With Myelofibrosis
The targeted therapy momelotinib may offer clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, for patients with myelofibrosis, according to a novel study published by Srdan Verstovsek, MD, PhD, and colleagues in The Lancet. The findings support...
Association of Immune-Related Gene-Expression Signatures and TILs With Outcomes in Early-Stage, HER2-Positive Breast Cancer
In a study reported in JAMA Oncology, Aranzazu Fernandez-Martinez, MD, PhD, and colleagues found that several B-cell–related gene signatures provided better prediction of pathologic complete response and event-free survival than tumor-infiltrating lymphocyte (TIL) levels among patients with...
Immunotherapy Combined With Targeted Therapy in Patients With BRAF V600E–Mutated Colorectal Cancer
In one of the first clinical trials combining immunotherapy and targeted therapy for patients with BRAF V600E–mutated colorectal cancer, researchers discovered that a combination regimen of dabrafenib, trametinib, and spartalizumab resulted in long-lasting responses. The study findings published by ...
Kohei Shitara, MD, on Gastric or Gastroesophageal Junction Adenocarcinoma: Recent Data on Zolbetuximab Plus mFOLFOX6
Kohei Shitara, MD, of Japan’s National Cancer Center Hospital East, discusses the SPOTLIGHT study’s phase III findings on zolbetuximab plus mFOLFOX6 as first-line treatment for patients with the biomarker claudin-18.2–positive and HER2-negative locally advanced unresectable or metastatic gastric or ...
Two Methods Studied in Defining Prognosis for Patients With ER-Positive, Node-Positive Breast Cancer
In a study reported in the Journal of Clinical Oncology, Corey W. Speers, MD, PhD, and colleagues found that the sensitivity to endocrine therapy (SET2,3) index and the 21-gene breast recurrence score (RS) were not correlated in defining prognosis among postmenopausal patients with estrogen...
FDA Grants Accelerated Approval to Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
On January 27, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pirtobrutinib (Jaypirca) for patients with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BRUIN Efficacy was...
FDA Approves Elacestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
On January 27, the U.S. Food and Drug Administration (FDA) approved elacestrant (Orserdu) for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine...
Souya Nunobe, MD, PhD, on Gastric Cancer: 5-Year Follow-up on S-1 Chemotherapy for Stage II Disease
Souya Nunobe, MD, PhD, of Japan’s Cancer Institute Hospital and the Japanese Foundation for Cancer Research, discusses 5-year follow-up results of the phase III OPAS-1 trial, which compared four and eight courses of S-1, a novel oral fluoropyrimidine derivative adjuvant chemotherapy for patients...
Sotorasib in Previously Treated Patients With KRAS G12C–Mutated Advanced Pancreatic Cancer: In Conversation With The ASCO Post
On this episode, Chandrakanth Are, MBBS, MBA, FSSO, FRCS, FACS, Professor of Surgical Oncology and Global Health at University of Nebraska Medical Center, and an editorial advisor for The ASCO Post, holds a conversation with John H. Strickler, MD, a medical oncologist at Duke University Medical...
Risk of Subsequent Gastrointestinal Tract Malignancies After Blood or Marrow Transplantation
In a study reported in JAMA Oncology, McDonald et al found that receipt of blood or marrow transplantation (BMT) was associated with an increased risk of subsequent malignant neoplasms of the gastrointestinal (GI) tract. As stated by the investigators, “Survivors of BMT are at increased risk of...
Addition of Pazopanib to Concurrent Radiotherapy and Paclitaxel in Anaplastic Thyroid Cancer
In a phase II trial (NRG/RTOG 0912) reported in The Lancet Oncology, Sherman et al found that the addition of pazopanib to concurrent radiotherapy and paclitaxel did not improve overall survival in patients with anaplastic thyroid cancer. Study Details In the U.S. multicenter, double-blind trial,...
New Analysis Sheds Light on Potential Link Between Ovulation and Ovarian Cancer
Individuals who ovulate for longer over their lifetimes may have a higher risk of developing ovarian cancer, suggesting that suppressing ovulation can lower this risk, according to a new study published by Fu et al in the Journal of the National Cancer Institute. The researchers also offered clues...
New Study Shows Increased Cancer Mortality Among Patients With Type 2 Diabetes in England
New research shows that patients with type 2 diabetes may experience a substantially higher rate of cancer mortality than the general population—by 18% for all cancers combined, 9% for breast cancer, and as much as 2.4-fold for colorectal cancer—according to a new study published by Ling et al in...
Trends in Use of Next-Generation Sequencing in U.S. Patients According to Genetic Ancestry
In a study reported in a letter to the editor in The New England Journal of Medicine, Mata et al found that U.S. individuals of African ancestry and Hispanic patients made up an increasing proportion of patients undergoing next-generation sequencing of tumor samples over a 9-year period ending in...
FDA Approves Pembrolizumab as Adjuvant Treatment for NSCLC
On January 26, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage IB (T2a, ≥ 4 cm), II, or IIIA non–small cell lung cancer (NSCLC). KEYNOTE-091 Efficacy was evaluated in...
Julien Taïeb, MD, PhD, on Treating Colorectal Cancer With Trifluridine and Tipiracil Plus Bevacizumab
Julien Taïeb, MD, PhD, of Hôpital Européen Georges Pompidou, Université Paris-Cité, discusses the clinical implications of new phase III findings from the SUNLIGHT study, which showed that trifluridine and tipiracil (FTD/TPI) plus bevacizumab resulted in improved outcomes compared with FTD/TPI...
ctDNA Analysis May Predict Optimal Treatment for Patients With GIST
Circulating tumor DNA (ctDNA) analysis of KIT exon mutations may help predict which second-line therapy is best for patients with advanced gastrointestinal stromal tumor (GIST), according to data presented by Bauer et al during the January ASCO Plenary Series session (Abstract 397784). An...
Risk of Major Psychiatric Disorders Among Survivors of Childhood and Adolescent Cancers
In a Taiwanese study reported in the Journal of Clinical Oncology, Hsu et al found that survivors of childhood and adolescent cancers were at a significantly increased risk of multiple major psychiatric disorders compared to those without cancer. Study Details The study used data from a...
Receiving Chemotherapy in the Afternoon May Improve Treatment Outcomes in Some Patients With DLBCL
Utilizing chronochemotherapy—a method aimed at delivering chemotherapy at a time when the body is least vulnerable to its harmful effects and when the cancer cells are at their most vulnerable—may improve the outcomes of some patients with diffuse large B-cell lymphoma (DLBCL), according to a novel ...
Undaunted
Soon after my marriage, in 2003, I noticed swelling in the glands around my throat. Although I otherwise felt fine, I went to see my primary care physician for a checkup and a blood test. The results of the test showed that I had an abnormally high number of lymphocytes circulating in my...
Communicating Prognosis: A Core Competency of Patient-Centered Oncology Care
Most of us have felt our stomachs sink as we opened a patient’s radiology or laboratory report and realized the patient faced a grave situation. If we’re lucky, we have a couple of days before a scheduled patient appointment to prepare ourselves to deliver that bad news. Other times, we may have...
Inaugural Recipients of the Lubin Family Foundation Scholar Award Named
The four inaugural recipients of the Lubin Family Foundation Scholar Award have been announced by Dana-Farber Cancer Institute and the Richard K. Lubin Family Foundation. Lubin Scholars are among the most promising physician-scientists pursuing cancer-relevant basic or translational...
Remembering Breast Cancer Pioneer Isaac Craig Henderson, MD
Isaac Craig Henderson, MD, passed away at the age of 81 at his home in San Francisco on December 26, 2022, after a brief illness. Dr. Henderson was an internationally known medical oncologist who specialized in breast cancer, beginning his career at Harvard’s then-designated Sidney Farber Cancer...
Expert Point of View: Nancy Chan, MD
Nancy Chan, MD, Director of Breast Cancer Clinical Research at NYU Langone’s Perlmutter Cancer Center, New York, commented on the monarchE analysis for The ASCO Post. She noted that the study investigated the addition of adjuvant abemaciclib (an oral CDK4/6 inhibitor) to endocrine therapy in a...
Update From monarchE: Benefit of Abemaciclib Increases Over Time in Early-Stage Breast Cancer
Results of a planned interim overall survival analysis of the phase III monarchE trial offered further support for the addition of abemaciclib to adjuvant endocrine therapy for patients with hormone receptor–positive, HER2-negative, node-positive, high-risk disease, according to Stephen R.D....
Expert Point of View: Jaime A. Suarez-Londono, MD
Jaime A. Suarez-Londono, MD, a medical oncologist at NYU Langone’s Perlmutter Cancer Center and Assistant Professor of Medicine at NYU Grossman School of Medicine, said the results of the ASAP study provide a basis for discussion with the transplant team. “The landscape of treatment of acute...
Intensive Remission Induction Chemotherapy vs Less Intensive Approach Prior to Transplant for Relapsed/Refractory AML
Intensive salvage therapy with the goal of achieving complete remission prior to allogeneic hematopoietic cell transplantation (alloHCT) may not be necessary in some patients with relapsed or refractory acute myeloid leukemia (AML), according to the results of the phase III ASAP trial presented at...
Andrea Schietinger, PhD, to Present 2023 AACR–Irving Weinstein Foundation Distinguished Lecture
The American Association for Cancer Research (AACR) will award the 19th AACR–Irving Weinstein Foundation Distinguished Lectureship to Andrea Schietinger, PhD, during the 2023 AACR Annual Meeting, held April 14–19, in Orlando, Florida. Dr. Schietinger, an associate member of the Immunology Program...
KU Medical Center Researchers Receive R01 Grant From NCI to Improve Access to Targeted Cancer Treatments for Rural Patients
Precision medicine has revolutionized cancer treatment—but only for patients who have access to treatments. Nearly 2 million people in the United States are diagnosed each year with cancer, but access to targeted treatments varies widely, and only about half of the eligible people receive them,...
The Influence of Structural Racism and Poverty on Outcomes in Leukemia
In the United States, Black American patients with acute myeloid leukemia (AML) have notably worse survival outcomes compared to White patients. In addition, Black patients are less likely to receive intensive chemotherapy and undergo allogeneic stem cell transplants. Many researchers have reported ...
